C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

Submitted by Anonymous on

MarketBeat Week in Review – 12/18 - 12/22 C4 Therapeutics NASDAQ: CCCC outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays’ 28th Annual Global Healthcare Conference, highlighting progress in multiple myeloma and an upcoming...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

Submitted by Anonymous on

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab MarketBeat Fri, March 13, 2026 at 7:11 PM CDT 6 min read In this article: CCCC PFE C4 Therapeutics logo Key Points C4 has...

Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R

Submitted by Anonymous on

AbstractBackground The exon 19 deletion (19 Del) and the exon 21 L858R point mutation (21 L858R) are two main subtypes of EGFR-mutant lung adenocarcinoma (LUAD) with distinct response to targeted treatment and immunotherapy. Understanding the intratumor heterogeneity (ITH) of EGFR-mutant...

Xiao Chai Hu Tang-derived decoction (Tung-Yi Fang) suppresses triple negative breast cancer cells in vitro and in vivo via regulating EGFR/AXL-mediated signaling

Submitted by Anonymous on

BackgroundTriple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. Xiao Chai Hu Tang (XCHT), a classical Abstract Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. Xiao Chai Hu...

Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE PR Newswire Thu, March 12, 2026 at...

Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity

Submitted by Anonymous on

Abstract Oligoprogressive disease (OPD) in non-small-cell lung cancer (NSCLC) is a clinical entity with peculiar behavior and treatment. OPD patients, during systemic therapy, may receive local ablative treatment (LAT) with survival benefit. The importance of OPD and the role of...

The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study

Submitted by Anonymous on

Abstract Background and Objectives: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and remains a leading cause of cancer-related mortality worldwide. EGFR-targeted tyrosine kinase inhibitors (TKIs) have substantially improved outcomes in EGFR-mutant NSCLC; however, primary...

Synergistic Effect of Baicalein Combined With Luteolin by Inhibiting the EGFR/NFκB Signaling Pathway in Hepatocellular Carcinoma Cells

Submitted by Anonymous on

Liver cancer is the malignancy with the highest mortality rate among digestive system cancers worldwide. Flavonoid plant extracts have shown significant safety and extensive function, especially anti-tumor activity. In this study, the therapeutic effects of a combination of baicalein and...

Subscribe to Newsfeed